Involvement of PKC delta (PKCδ) in the resistance against different doxorubicin analogs

@article{Bessone2010InvolvementOP,
  title={Involvement of PKC delta (PKCδ) in the resistance against different doxorubicin analogs},
  author={Mar{\'i}a In{\'e}s D{\'i}az Bessone and Dami{\'a}n E. Berardi and Paola Bernadette Campod{\'o}nico and Laura Beatriz Todaro and Leonard Lothstein and Elisa Dora Bal de Kier Joff{\'e} and Alejandro J. Urtreger},
  journal={Breast Cancer Research and Treatment},
  year={2010},
  volume={126},
  pages={577-587}
}
Doxorubicin is an anti-tumor antibiotic widely used in the management of cancer patients. Its main mechanism of action involves the generation of DNA damage and the inhibition of topoisomerase II, promoting apoptosis. AD 198 is a novel doxorubicin analog devoid of DNA binding and topoisomerase II inhibitory capacities. It has been proposed that AD 198 induces apoptosis by activating protein kinase C delta (PKCδ); a PKC isoform described as growth inhibitory in a large number of cell types. We… CONTINUE READING
9 Citations
40 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 40 references

cytoplasmic versus nuclear—a fork in the road

  • L Lothstein, Israel MSweatman TW Anthracycline drug targeting
  • Drug Resist Updat 4:169–177 Breast Cancer Res…
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…